BRISTOL-MYERS SQUIBB COMPANY
BMY US1101221083
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Elkins David V EX VP |
47.33 USD |
56,000 Sold |
2,650,480 USD |
02/09/2025 | 02/09/2025 |
Short Bartie Wendy EX VP |
44.23 USD |
378 Sold |
16,719 USD |
02/08/2025 | 02/08/2025 |
Short Bartie Wendy EX VP |
44.23 USD |
378 Sold |
16,719 USD |
02/08/2025 | 02/08/2025 |
Hickey Benjamin PR |
38.01 USD |
97 Sold |
3,702 USD |
09/05/2025 | 09/05/2025 |
Hickey Benjamin PR |
38.01 USD |
97 Sold |
3,702 USD |
09/05/2025 | 09/05/2025 |
Hirawat Samit EX VP |
47.58 USD |
4,250 Bought |
202,215 USD |
25/04/2025 | 25/04/2025 |